We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+2.89%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
+$29.2M
Cap. Flow
+$147M
Cap. Flow %
5.13%
Top 10 Hldgs %
48.59%
Holding
107
New
12
Increased
2
Reduced
2
Closed
19

Top Buys

Rank Stock Value
1
TYRA icon
Tyra Biosciences
TYRA
+$121M
2
TNGX icon
Tango Therapeutics
TNGX
+$82.4M
3
BPMC
Blueprint Medicines
BPMC
+$39.6M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$37.4M
5
NUVL
Nuvalent
NUVL
+$35.1M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$63.2M
2
AMRN
Amarin Corp
AMRN
+$26.3M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$24M
4
AGEN
Agenus
AGEN
+$22M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$20.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.15%
2 Financials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ODT
51
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$16.3M 0.57%
5,607,086
– –
MIST icon
52
Milestone Pharmaceuticals
MIST
$138M
$14.7M 0.51%
2,572,194
– –
BCEL
53
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$13.7M 0.48%
2,202,333
– –
RNAC icon
54
Cartesian Therapeutics
RNAC
$229M
$13.7M 0.48%
109,469
– –
XENE icon
55
Xenon Pharmaceuticals
XENE
$6.06B
$13.1M 0.46%
857,000
– –
FSTX
56
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$12.8M 0.45%
1,751,428
– –
ACHL
57
DELISTED
Achilles Therapeutics
ACHL
$12M 0.42%
1,536,016
– –
NGNE icon
58
Neurogene
NGNE
$656M
$10.9M 0.38%
75,053
– –
NGM
59
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$10.5M 0.37%
500,000
– –
ELEV
60
DELISTED
Elevation Oncology
ELEV
$10.5M 0.37%
1,341,530
– –
TLIS
61
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$9.69M 0.34%
103,400
– –
IMMP
62
Immutep
IMMP
$56.3M
$9.68M 0.34%
2,500,000
– –
ERAS icon
63
Erasca
ERAS
$6.3B
$9.55M 0.33%
+450,000
New +$9.28M
SLDB icon
64
Solid Biosciences
SLDB
$794M
$8.93M 0.31%
248,972
-33,333
-12% -$1.42M
LITS
65
Lite Strategy Inc
LITS
$32.8M
$8.04M 0.28%
145,655
– –
VINC
66
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$7.28M 0.25%
22,500
– –
EPIX
67
DELISTED
ESSA Pharma
EPIX
$5.5M 0.19%
687,000
– –
IRON icon
68
Disc Medicine
IRON
$2.94B
$5.25M 0.18%
43,333
– –
ASMB icon
69
Assembly Biosciences
ASMB
$498M
$5.22M 0.18%
125,000
– –
BLSA
70
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.98M 0.17%
500,000
– –
RACB
71
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.92M 0.17%
500,000
– –
PANA
72
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.17%
500,000
– –
JYAC
73
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.88M 0.17%
500,000
– –
NAUT icon
74
Nautilus Biotechnolgy
NAUT
$124M
$4.61M 0.16%
750,000
– –
ORIC icon
75
Oric Pharmaceuticals
ORIC
$1.15B
$4.18M 0.15%
200,000
– –
1 2
3
4 5

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Boxer Capital held 107 positions worth $2.86B, up 1% from $2.83B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Boxer Capital deployed $147M of net new capital in Q3 2021, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Tyra Biosciences: 6,323,359 shares worth $111M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Solid Biosciences, an estimated $1.42M trimmed.

  • Boxer Capital's largest Q3 2021 buy was Tyra Biosciences: 6,323,359 shares worth $111M.
  • Boxer Capital added most to Kinnate Biopharma Inc. Common Stock in Q3 2021, an estimated $17M increase.
  • Boxer Capital's biggest Q3 2021 reduction was Solid Biosciences, cutting an estimated $1.42M.
  • Boxer Capital fully exited Seagen Inc. Common Stock in Q3 2021, selling an estimated $63.2M.
  • Boxer Capital's ten largest holdings make up 49% of its $2.86B portfolio in Q3 2021.
  • Boxer Capital opened 12 new positions and closed 19 in Q3 2021.
  • Boxer Capital's portfolio value rose 1% quarter-over-quarter to $2.86B.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.